Scholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) P/S ratio
As of 6 November 2026, Scholar Rock Holding Corporation (SRRK) trades at a P/S ratio of 130×. Over the past ten years it has ranged from 0.0× (December 2019) to 166× (August 2026); the current reading is higher than 95% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2022 | 12.1× | (75.09%) |
| FY2021 | 48.5× | (49.95%) |
| FY2020 | 96.8× | 446.72% |
| FY2019 | 17.7× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Mar 2022 | 10.2× | (78.94%) |
| Dec 2021 | 48.5× | (27.17%) |
| Sep 2021 | 66.5× | (0.71%) |
| Jun 2021 | 67.0× | (45.16%) |
| 9 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| MANE Veradermics Incorporated compare | n/m |
| IMVT Immunovant, Inc. compare | n/m |
| KOD Kodiak Sciences Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | 4.8× |
| SRRK Scholar Rock Holding Corporation | 126× |
| COGT Cogent Biosciences, Inc. compare | 220× |
| CGON CG Oncology, Inc. compare | 919× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on SRRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement